Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Provides An In-Depth Insight Of Sales Analysis-US STEM CELL, INC. – Fashion…

This new report by Eon Market Research, titled Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Research Report, 2015 2025 offers a comprehensive analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies industry at a global as well as regional and country level. Key facts analyzed in this report include the Autologous Stem Cell and Non-Stem Cell Based Therapies market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2020-2025. This report primarily focuses on the study of the competitive landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors in global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market presents market size in terms of volume and value (or whichever applicable) for the entire forecast period and also offers CAGR for the forecast period under consideration.

Grab a sample of this report and get instant 10% discount @ https://www.eonmarketresearch.com/sample/55837

**If you have any special requirements, please let us know and we will offer you the report as you want.**

Key trends analyzed for the prospective readers of this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include major demand drivers, restraints and key opportunities prevailing in the industry. Certain high-level analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies market such as value chain analysis, Porters five forces analysis, SWOT analysis, and market attractiveness analysis to cover all the circumstances affecting this Autologous Stem Cell and Non-Stem Cell Based Therapies industry is also covered in this report. Portfolio analysis helps to understand the product mix of leading companies in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry.

This report focuses on top manufacturers in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market, with revenue production, sales, gross margin, and market share for each manufacturer, covering

U.S. STEM CELL, INC.Brainstorm Cell TherapeuticsCytoriDendreon CorporationFibrocellLion BiotechnologiesCaladrius BiosciencesOpexa TherapeuticsOrgenesisRegenexxGenzymeAntriaRegeneusMesoblastPluristem Therapeutics IncTigenixMed cell EuropeHolostemMiltenyi Biotec

Place An Inquiry Before Buying @ https://www.eonmarketresearch.com/enquiry/55837

Consumption, production, capacity, market share, growth rate, and prices are included for each product type segment of Autologous Stem Cell and Non-Stem Cell Based Therapies market

Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

Consumption, market share and growth rate for each application segment of Autologous Stem Cell and Non-Stem Cell Based Therapies market

Neurodegenerative DisordersAutoimmune DiseasesCancer and TumorsCardiovascular Diseases

The Autologous Stem Cell and Non-Stem Cell Based Therapies market report presents all-inclusive information on raw materials suppliers, equipment suppliers, manufacturing cost, capacity, production, profit margin, capacity utilization rate, etc. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market report also covers a systematic geographical analysis.

Key regions analyzed in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market include; North America, Latin America, Europe, Asia Pacific, and Middle East Africa. The country-level analysis included for U.S., UK, France, Germany, Russia, China, Japan, India, and Brazil. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry report provides detailed bifurcation of each segment on global, regional and country level. In a word, the Autologous Stem Cell and Non-Stem Cell Based Therapies market report provides major statistics on the state of the industry and is a valuable source of direction and control for companies and individuals interested in the market.

About Us-

Eon Market Research is one of the unique research reports and service providers that help to find out the different research reports of Chemical, food and beverages, consumer goods, Energy, Medical devices and Pharmaceutical and Health Care.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: sales@eonmarketresearch.com

Read the original here:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Provides An In-Depth Insight Of Sales Analysis-US STEM CELL, INC. - Fashion...

China optimises treatment for COVID-19 – The News International

China optimises treatment for COVID-19

BEIJING: China has expanded and optimized the utilization of drugs and therapies in the treatment of the novel coronavirus disease (COVID-19) to block the conversion of mild cases to severe cases and save critically ill patients.

Tocilizumab, with the common brand name Actemra, has been included in Chinas latest version of diagnosis and treatment guidelines on COVID-19. Zhou Qi, deputy secretary-general and an academician of the Chinese Academy of Sciences, said at a press conference Friday that the drug Tocilizumab has been found effective to block the inducement of the inflammatory storm.

In an initial clinical trial, Tocilizumab was used in 20 severe COVID-19 cases. And the body temperatures of all the patients dropped within one day. Nineteen of the patients were discharged from the hospital within two weeks, and one got better, according to Zhou.Currently, the drug is under clinical trials in 14 hospitals in Wuhan, the epicenter of the epidemic, Zhou said.

As of March 5, a total of 272 severe patients had been treated with Tocilizumab.In addition to Tocilizumab, Chloroquine Phosphate and some traditional Chinese medicines, as well as convalescent plasma therapy, have been included in the treatment guideline. China is also pushing forward the utilization of some advanced technologies such as stem cell and monoclonal antibody technologies in the treatment of severe cases, said Wu Yuanbin, director-general of science and technology for social development of the Ministry of Science and Technology (MOST).

The drug Chloroquine Phosphate has been used in treating 285 critically ill COVID-19 patients in a hospital in Wuhan, and no obvious adverse reactions have been found so far, said Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the MOST.

Two clinical trials for Remdesivir are ongoing, and we are looking forward to seeing the results, Sun said.The combination of traditional Chinese medicines and Western medicines has shown good results in the treatment of COVID-19. Statistics show that 90 percent of the patients in Hubei Province have been treated with traditional Chinese medicines, Sun said.China has also made progress in convalescent plasma therapy. So far, 154 severe patients have received such treatment with good effect, according to Sun.

As of March 5, a total of 919 rehabilitants had donated some 294,450 ml plasma, and in Hubei Province alone, 450 convalescents had donated more than 160,000 ml, providing valuable data, materials and information for the treatment of other patients and development of antibodies and immunoglobulins, said Zhou Qi.

In addition, the clinical research of stem cell therapy has been carried out in some hospitals in Beijing and Harbin, capital of northeast Chinas Heilongjiang Province, and the preliminary trials show that the therapy is safe and effective, according to Sun.

Next, Chinese researchers will strengthen the integration of traditional Chinese medicines and Western medicines, combine antiviral therapy and immunomodulatory therapy and make all efforts to cure more patients, Sun said.

In response to some reports on the variation of the novel coronavirus, Zhou Qi said further research on more cases is needed.

We are closely observing the degree of the virus mutation and conducting related research. So far the virus variation hasnt affected the development of drugs, antibodies and vaccines, Zhou added.

Excerpt from:
China optimises treatment for COVID-19 - The News International

Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks – Yahoo Sports

The Angels announced that starter Griffin Canning is getting a biological injection in his ailing elbow and will be re-evaluated in 3-4 weeks time. Canning was recently diagnosed with both UCL and joint issues in his pitching elbow.

The phrasing of the announcement is interesting. The word biological generally leads me in two different directions with this sort of injury. Many baseball players have been treated with platelet-rich plasma (PRP) injections for a variety of issues in recent years, but the Angels have also used stem cell injections to try to treat UCL woes.

Andrew Heaney, Garrett Richards and Shohei Ohtani all got stem cell treatments for their elbows. All three also eventually wound up getting Tommy John surgery. Im not willing to go as far as the LA Times article did in condemning the treatments as useless, seeing as a sample size of three is rather small. Theyre also not the only players who have ever been treated with stem cells. CC Sabathia, for instance, got a stem cell injection for his bad knee.

Regardless of what the treatment is or isnt, its a positive sign that Cannings injury wasnt deemed dire enough to immediately merit surgery. Canning isnt going to be ready for Opening Day either way, but if the injection works he may be able to pitch at some point this season. Goodness knows that the Angels rotation needs all hands on deck, even after the team signed both Dylan Bundy and Julio Teheran this winter.

Follow @StelliniTweets

Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks originally appeared on NBCSports.com

Go here to read the rest:
Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks - Yahoo Sports

Padres notes: Tommy Pham expected to play left field soon; Fernando Tatis Jr. gaining strength – The San Diego Union-Tribune

There can be an exhale regarding one of the most important pieces to the Padres plan for success in 2020.

It appears Tommy Pham will meet the goal the Padres had all along of him playing left field by mid-March, as manager Jayce Tingler said Pham is on the verge of doing just that.

We expect him to get in a game defensively, if its not coming off (Tuesdays) off day, it could be before that, Tingler said Friday. I think in the next couple days we feel confident to get him out there.

Pham, acquired in a December trade that sent Hunter Renfroe to Tampa Bay, played the final couple months of 2019 with a partially torn UCL in his right (throwing) elbow. He underwent treatment, including stem cell and platelet-rich-plasma (PRP) injections over the offseason. He was not cleared to swing a bat until mid-December and didnt start throwing until spring training.

On Friday, Pham played catch for a third straight day. He moved up to 150 feet, which is 25 feet beyond where he was at the start of the week and 50 feet from the target distance for him to be cleared to play in left field.

Big day, said Pham, who has regularly taken part in outfield drills without throwing.

Pham was one of five major league players to hit at least 21 home runs and steal at least 25 bases in 2019. He is one of just four players in the majors to have at least a .850 OPS and 65 stolen bases since 2017.

Shortstop Fernando Tatis Jr. could practice full Sunday and play in a game as soon as Monday following a bout with the flu that kept him away from the teams complex for four days this week.

Tatis, who has not played in a game since Feb. 28, did some limited work (throwing and in the cage) for a second day Friday.

You never want see somebody get sick, Tingler said. If youre going to get sick, three weeks left in camp would be more ideal than with four or five days to go.

Opening day is March 26.

Greg Garcia is back to doing what he did so well for the Padres last season, his first in his hometown.

He is hitting right-handers regularly. He has four hits in his past six at-bats against righties and is 5-for-10 against them this spring, including his two-run homer Thursday.

But where the Valhalla High grad made 73 of his 74 starts against right-handed pitchers, spring training lineups are not filled out with opposing pitchers in mind. Garcias first three at-bats this spring were against lefties, against which he is a career .186 hitters (.293 OBP) compared to the .258 (.369) he hits against righties.

Its fun, Garcia said. Its just getting at-bats, trying to figure out the strike zone again. Thats what I take away from it. Im just trying to take good at-bats.

Garcia, who is battling for a roster spot as a utility infielder and part-time starter at second base, is 1-for-6 against lefties this spring.

Read more from the original source:
Padres notes: Tommy Pham expected to play left field soon; Fernando Tatis Jr. gaining strength - The San Diego Union-Tribune

Dubai is the ‘new Beverly Hills of the Middle East’: Here’s why – Gulf News

Image Credit: Getty Images/iStockphoto

Dubai: It's an industry on the rise, driven by social media before-and-after ads.

And it's ramping up the speed by which Dubai is fast becoming the "new Beverly Hills of the Middle East."

Already, cosmetic surgery has topped the list in medical tourism in Dubai. According to a Dubai Health Authority (DHA) report, the emirate has the highest number of cosmetic surgeons per capita in the region about 50 specialists for a million people.

It's a huge market.And a money-spinner: Price ranges from Dh150-250 for a filler to Dh40,000 for a detailed body sculpting procedure.

Globally, the cosmetic surgery market size is projected to reach $21.97 billion with 7.8% annual growth rate by 2023, according to a Medgadget report.

These are the most common surgery options:

To put this in perspective, we talked to several people.

Myra J., a belly dancer working at a Dubai hotel. She was unhappy. Saddle bags on her thighs were making her performance less graceful. She honestly feared she would be jobless soon.

On a weekend, she checked into a leading aesthetic clinic and the surgeon trimmed the pockets of fat around her thighs, sculpting her body back into perfect shape.

It took her a week to recover and get back to work, but she is delighted with her shapely thighs and feels happier than ever before.

'Ageing gracefully'

Nina M., (52), always loved how beautiful her eyes were and how youthful her cheeks looked.

Last year, nowever, as she got busy with her sons marriage preparations, she started to experience bouts of anxiety at the sight of slowly encroaching bags under her eyes and a slight droop in her cheeks.

I wanted to look and feel my best and thought a filler and a round of botox were harmless indulgences. It took me just an hour at the clinic and the results were amazing. I am glad I was able to stop the onslaught of aging in time.

"Its beautiful to age gracefully, but we all do use creams and gels to delay the process. I think of these minor injectibles as tools in our make-up bag.

"I have used fillers and Botox twice since last year, combined with my beauty regimen. I feel it has given me not just confidence but also psychological boost. I would recommend it to everyone.

Anna M was a physical trainer but vexed with her body shape as she had a masculine build.

- Anna M, a physical trainer

This was affecting her work. Most women were intimidated by her personality and she was losing self-confidence.

Four years ago, she went in for breast implants and her life changed.

Addiction to surgery?

People talk about getting addicted to cosmetic surgery. But that is not so. Most people approach a cosmetic surgeon only when they cannot deal with a physical issue themselves and just like one needs medicine when one is ill, cosmetic surgery acts as a solution to boost confidence and self-esteem.

"Look at how people have reclaimed their health with gastric bypass!

- Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society

Changing the world one person at a time and providing them with an incredible burst of confidence, aesthetic and cosmetic surgeons in the UAE have built a practice of reliability that can take as little as one hour to a day to transform your personality.

Welcome to the multi-million dirham cosmetic surgery industry in the UAE.

It is the toast of medical tourism in the region, with a high footfall of Gulf and Asian medical tourists as well as resident expatriates.

The industry has accelerated at a speed that is making Dubai be hailed as the new Beverly Hills of the Middle East.

Cosmetic or Plastic Surgery?

These are two different concepts. Cosmetic surgery refers to aesthetic surgery and revolves around enhancement of physical features of an individual and is elective.

This includes procedures such as:

Plastic surgery, on the other hand, is a surgical speciality dealing with life-saving procedures of re-construction of the face and body owing to congenital defects, disfigurement due to accident, trauma, burns, tumour removal due to diseases such as cancer.

In most cases, plastic surgery is not elective.

Dh12b Medical tourism sales in 2018

Since the time pop stars began to inundate Instagram with images of their perfect bodies, dazzling smiles, flawless skin and enviable hair volume, elective procedures have become commonplace with teenagers as young as 13 who are going in for instant fixes.

While some procedures require a couple of days of hospital stay and being out of circulation for a while, many quick fixes are carried out during lunch breaks in one-hour durations.

Highest per capita cosmetic surgeons in UAE

Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society, told Gulf News: Cosmetic surgery tops the list in medical tourism in Dubai and according to a 2015 report of Dubai Health Authority (DHA), Dubai has the highest number of cosmetic surgeons per capita in the region about 50 specialists for a million people.

- Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery

Dr Parashar added: The field has grown beyond expectations and much of the credit goes to the development of a world-class infrastructure in this field and the corresponding health regulations.

"Today, in Dubai, most Day Care Surgery centres where most of the plastic surgery procedures are carried out have the best international accreditations.

Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery, said: Much of the advancement in plastic and cosmetic surgery is work in progress as surgeons are constantly upgrading themselves with techniques, technologies.

The UAE is keeping abreast of the best that is taking place in the world. In the last five years or so, there have been tremendous advancements in cosmetic and plastic surgery in the UAE.

BEVERLY HILLS AND PLASTIC SURGERY

It's where leading practitioners are rated by customers who give feedback and grade their experience with plastic surgeons according to a five-star rating system.

In this posh district, located within 5.7 square miles and surrounded by the cities of Los Angeles and West Hollywood, one of most popular procedures is breast augmentation, according to online directory and crowd-sourced review forum Yelp.

"We have the top plastic surgeons of the world come here to do surgeries and the UAE hosts two major international plastic surgery conferences each year.

Soaring revenues

With greater acceptance and broadening of scope for the discipline, it is evident that plastic surgery is a major revenue earner and places UAE as one of the leading medical tourism destinations in the region.

From a price range of Dh150-250 for a filler to Dh40,000 for a detailed body sculpting procedure, these procedures are money-spinners.

Together, the plastic and cosmetic surgery is a multimillion dirham business in the UAE. While there are no exact figures available, safe estimates can be made, say surgeons.

MULTIMILLION BUSINESS

There are 30 hospitals in Dubai, of which 70 per cent are internationally accredited. The emirate aims to build 22 hospitals by 2020 18 private and 4 public hospitals.

In Dubai, at least 50 per cent of its 30 hospital offer cosmetic and plastic surgery options.

30 number of hospitals in Dubai, of which 70 per cent are internationally accredited

Besides that there are about 150 Day Care Surgery centres and 400 aesthetic clinics in Dubai.

All of them offer a bouquet of cosmetic surgery procedures and their average annual revenue is between Dh4-6 million a year.

400 Number of aesthetic clinics in Dubai

If one were to compute that with the numbers of facilities including hospitals, the annual revenue from cosmetic surgery would run into many millions of dirhams annually.

High on medical tourism

Currently, Dubai aims to attract 500,000 medical tourists a year by end 2020.

In a short priod of time, Dubai has managed to be ranked 17 among the top 25 global destinations for medical tourism and cosmetic surgery, along with fertility, orthopaedic, dental and wellness disciplines in the list of most-billed medical procedures.

40% percentage of tourists who come to Dubai come only for medical tourism. Medical tourism sales topped Dh12 billion in 2018, a 5.5% jump in the number of medical tourists

Based on official data, about 46 per cent of the current medical tourists in Dubai come from Asian countries. About a quarter (25 per cent), come from GCC and Arab countries and 13 per cent from African countries, and the remaining 16 per cent from other countries, mainly the UK and Commonwealth of Independent States (CIS) countries.

In fact, 40 per cent of tourists who come to Dubai come only for medical tourism.

- Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai

Medical tourism sales topped Dh12 billion in 2018, with a 5.5 per cent overall increase in medical tourists.

Medical tourists

Dubai attracted a total of 640,542 international and domestic medical tourists in 2018 (51 per cent were international patients).

European tourists consisting mostly of UK, French and Italian citizens, share 16 per cent of health and wellness tourists.

A substantial medical tourism revenue, it is evident, is earned through plastic and cosmetic surgery.

Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai, remarked: American Hospital Dubai, is one of the few facilities offering both comprehensive reconstructive and cosmetic surgery services.

"Our plastic surgeons are fully trained in both reconstructive and cosmetic surgery so we see a wide-ranging case mix, from severe trauma cases to cancer cases and of course, those opting for cosmetic surgery."

Most popular cosmetic surgery

Typically, these patients would be female, who done with having children and raising them, now wish to address the changes in their body. I also see a large number of male patients who want to correct problems associated with their chest with the help of liposuction.

Source: Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai

Most popular cosmetic surgery

"Typically, these patients would be female, who done with having children and raising them, now wish to address the changes in their body. I also see a large number of male patients who want to correct problems associated with their chest with the help of liposuction, said Dr Conroy.

Non-surgical treatments (neuro-modulators, fillers, etc) are still very popular and I have seen a trend in that patients are starting with such treatments at an earlier age.

Given the prestigious reputation of the hospital and the Dubai governments plan to promote medical tourism, I have noticed a huge influx of patients from Africa, Nigeria and Ghana in particular.

"These patients come mainly for cosmetic surgery, knowing that they are in the hands of a highly qualified surgeon, in a safe, luxurious facility, with standards second to none, said Dr Conroy.

Top six cosmetic surgery procedures in town

The procedures can be divided into categories:

Does health insurance cover plastic surgery?

"Reconstructive surgery such as correction of birth deformities such as a tuberous breast, cleft lip, hand deformities, skin transplant following burns, road trauma and breast augmentation and reconstruction following a mastectomy and rebuilding after a tumour resection is all covered under all leading health insurances. There is also new kinds of stem cell therapy being used to regenerate tissues and nerves especially in diabetic patients.

Know the rules:

The DHA has made it mandatory for all Day Care Surgery Centres, most of who carry out aesthetic procedures, to have one leading international accreditation from Canada, US, UK or Australia.

These accreditations were earlier mandatory for hospitals only, but from 2020, all Day Care Surgery centres compulsorily must have an international accreditation.

This ensures that an independent, international medical body enforces global health standards to grant them certification and in case of a sentinel event, conducts its independent inquiry and downgrades these places in case of a serious lapse.

DHA on its own has issued a 25-page manual on quality and regulations that is to be followed at all centres.

A close examination of the Day Care Surgery centres indicates several layers of quality control.

Pre surgery quality

This involves free consultation, especially in case of a second opinion or a first time patient seeking to enquire about a procedure based on his/her requirement. When a patient uploads a request on the website of a centre from anywhere in the world, the centre has to provide a detailed consultation free of charge.

Services available to a patient

Once the patient is convinced and comes in person to consult the doctor, quality is upheld in the pre-diagnostic tests that the patient has to undergo.

Infrastructure quality

DHA has graded Day Care Centres into A, B and C categories based on the level of medical facilities that can be accessed by a patient. Anaesthesia methods such as oral, epidural and general also help classify centres. For instance, hair transplant procedures can only be carried out in B and above grade clinics. Day Care Centres that conduct surgeries under general anaesthesia much be equipped with the Advance Cardiac Life Support (ACLS) with their surgeons and registered nurses being certified as trained in administering ACLS to a patient.

Patient safety protocol

There are very specific guidelines for patient safety and the doctor/surgeon must explain the procedure in detail to the patient and his/her family and obtain a written consent to go ahead after ascertaining that all risks and side-effects have been clearly explained to the patient.

Originally posted here:
Dubai is the 'new Beverly Hills of the Middle East': Here's why - Gulf News

Single-Cell Analysis of Ovarian Cortex Fails to Find Stem Cells – The Scientist

The first single-cell analysis of the human ovarian cortex revealed six main types of cells, but none of the oogonial stem cells that other researchers say they have isolated, according to a study published earlier this week (March 2) in Nature Communications. These findings are backed by the most advanced technologies, the authors say, and could put to rest a heated debate about the properties of the adult ovary that has raged for more than a decade.

The results of the experiment dont leave a lot of space for different interpretations, says Susana Chuva de Sousa Lopes, a developmental biologist at Leiden University Medical Center in the Netherlands who served on the PhD dissertation committee of coauthor Sarita Panula but was not involved in the research. It seems, she says, that cells previously identified as ovarian stem cells are in fact perivascular cells, which support blood vessel structure and help regulate blood flow.

But the discoverers of ovarian stem cells in adult mammals and other proponents of the cells existence are not convinced, citing methodological weaknesses of the new study.

Until relatively recently, scientific consensus was that a female mammals oocyte pool is fixed at birth. Adult ovaries, it was assumed, are simply unable to generate new eggs. But in 2004, Northeastern University reproductive biologist Jonathan Tilly and colleagues published findings that appeared to upend this understanding of oocyctes by presenting evidence of ovarian stem cells in adult mice.

A few years later, scientists in China claimed to have also found such germ line stem cells in the ovaries of adult mice, and showed that these cells could differentiate into functional eggs that gave rise to viable mouse pups. And in 2012, Tillys group reported the existence of germ cells in samples of human ovarian tissue, claiming that these cells could similarly generate oocytes in vitro and in vivo when injected into mice.

These findings generated a lot of publicity because they suggested that human fertility wasnt fixed after all. But the data has always been criticized, says Fredrik Lanner, an embryonic stem cell researcher at the Karolinska Institute and a coauthor on the newly published study that failed to find such stem cells.

We quite feel certain to say that in the human adult ovary in this cortex region, there is no cell that would be the oogonial stem cell.

Pauliina Damdimopoulou, Karolinska Institute

While some groups have been able to reproduce the results, others have tried and failed. Debates have erupted over methods, techniques, and protocols, and Tilly and his colleagues have published lengthy replies to those who have challenged their work. Today, the field is more or less divided into two camps regarding the existence of ovarian stem cells, says Chuva de Sousa Lopes.

To try to get to the bottom of the issue, Lanner and his collaborators harvested high-quality ovarian tissue samples from 21 healthy patients of reproductive age and isolated the ovarian cortex, the outer layer of the ovary where researchers claim to have found the elusive stem cells. The team used enzymes to break down the ovarian tissues, yielding 24,000 individual cells in total, then performed single-cell transcriptome and cell surface marker profiling, revealing six main cell types: oocytes, granulosa cells, immune cells, endothelial cells, perivascular cells, and stromal cells. None of the single-cell profiles matched those of reported ovarian stem cells.

When Lanner and colleagues stained the cells with an antibody against DDX4, a germ cell marker that is reported to select for oogonial stem cells, they found that they had instead isolated perivascular cells. The team then stained intact ovarian tissue and saw that the antibody similarly identifies perivascular cells. A comparison of the 24,000 cells to existing transcriptome data from both human fetal ovaries and the ovarian medulla, the inner region of the ovary, also failed to reveal any oogonial stem cells.

We quite feel certain to say that in the human adult ovary in this cortex region, there is no cell that would be the oogonial stem cell, says coauthor Pauliina Damdimopoulou, a cell biologist at the Karolinska Institute. She believes that other researchers have succeeded in using the DDX4 isolation technique to select and culture cells, but that what they have found are in fact perivascular cells and not oogonial stem cells.

This study again highlights that the DDX4 isolation technique is not something that can be used to isolate oogonial stem cells, University of Adelaide cell biologist Keith Jones, who was not involved in the work but coauthored a 2016 papersuggesting that the same antibody does not isolate DDX4 positive cells, writes in an email to The Scientist. It brings into question the existence of such stem cells, and leads us back to the dogma that prevailed previously in the fieldthe adult ovary does not contain oogonial stem cells.

Damdimopoulou also notes that she and her colleagues found that small, mature oocytes can slip through the filtration process, and when cultured, may appear as if they had been generated from stem cells. We think [the oocytes] were there all along from the beginning, she says. The formation of new vasculature by perivascular cells surrounding these oocytes, Chuva de Sousa Lopes suspects, could trigger dormant egg cells to become active and then mature, which might explain the results published by other labs.

Perivascular cells dont undergo meiosis, perivascular cells dont express meiotic genes, perivascular cells dont express germ cell genes.

Jonathan Tilly, Northeastern University

Others are not ready to give up on the idea of ovarian stem cells just yet. Deepa Bhartiya, a stem cell biologist at the National Institute for Research in Reproductive Health in India who was not involved with the research, has been working with ovarian stem cells since 2010 and says that they can be easily detected. Research with sheep ovarian tissues has shown that simple scraping of [the] ovary surface can show the presence of stem cells amongst the ovary surface epithelial cells, she writes in an email to The Scientist. The problem with the new study out of Sweden, Bhartiya says, is the speed at which the researchers spun their cellsmuch too slow to isolate the stem cells, which due to their small size do not pellet down at lower speeds and are therefore unknowingly discarded. Bhartiya writes that the study used novel techniques, but revealed nothing new: if sample preparation is not properone will get negative data.

Tilly argues that there are numerous methodological problems with the study. He says that at this point four independent groups have reported on the existence of oogonial stem cells, showing that the cells can generate new oocytes in both somatic ovarian tissue and outside the body in culture, and that they can undergo complete meiosis, a germ cell-specific event. Perivascular cells dont undergo meiosis, perivascular cells dont express meiotic genes, perivascular cells dont express germ cell genes, he says.

What the field really needs, says Chuva de Sousa Lopes, is more communication among researchers. The scientists that claim there are stem cells in the ovary and the scientists that are against that are somehow not really talking to each other, she says. I wish there would be more open dialogue, because sooner or later all these populations [of cells] will be clarified . . . and things will be more clear.

M. Wagner et al., Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells,Nat Commun,doi:10.1038/s41467-020-14936-3, 2020.

Amy Schleunes is an intern atThe Scientist. Email her ataschleunes@the-scientist.com.

View original post here:
Single-Cell Analysis of Ovarian Cortex Fails to Find Stem Cells - The Scientist

Coronavirus: China looking at using stem cell therapy to treat severe cases – The Straits Times

BEIJING (XINHUA) - Chinese researchers are studying the use of stem cell technology in the treatment of people critically ill with the coronavirus, the Science and Technology Daily reported.

Four Covid-19 patients who received stem cell treatment while in a serious condition have been discharged from hospital after recovering, and the clinical trial of the therapy will be further expanded, Vice-Minister of Science and Technology Xu Nanping, was cited by the paper as saying.

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells. They can become cells of the blood, heart, lungs or other body parts.

Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation, and inhibiting inflammatory response, experts say.

Stem cell therapy has also been used in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in treating Covid-19 in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration. Approvals by the ethics committee, and clinical observation and evaluation are in progress.

Another research team from the fifth medical centre of the Chinese PLA General Hospital is cooperating with hospitals and institutions in Wuhan - the epicentre of the epidemic - and northern China's Tianjin municipality to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating Covid-19 patients.

A research team at the School of Medicine of the Tongji University is studying universal lung stem cell therapy that can be widely used in the epidemic control. The therapy is expected to enter the clinical stage soon.

Professor Zuo Wei, head of the research team and the chief scientist of a national key research project on stem cells, said that the research now mainly focuses on improving the condition of critically ill Covid-19 patients.

He explained that when the patients are in a severe condition, the cause of deterioration and even death is the "inflammatory storm", when the human immune system is over-activated by the infection.

That will damage the lungs and impair breathing. Some severe patients may have respiratory failure.

"Lung inflammation and injury are the focus of the treatment of severe patients," Prof Zuo said.

The damage to lung tissue can be fatal, and stem cell therapy is expected to help repair the damage, Prof Zuo added.

Currently, three kinds of stem cells - mesenchymal, lung and embryonic stem cells - are used in treatments. Researchers usually inject stem cell products into the lungs.

Stem cells can improve the immune microenvironment in the lungs and reduce the risk of pulmonary failure caused by inflammation.

Stem cells have the potential of self-renewal and differentiation, and can develop into corresponding functional cells and alveoli, and then repair the damaged tissue, Prof Zuo said.

However, the wider use of stem cell technology to treat Covid-19 is still some time away.

The safety and effectiveness of a new drug or therapy need to be verified with sufficient clinical trials, Prof Zuo stressed.

Read more:
Coronavirus: China looking at using stem cell therapy to treat severe cases - The Straits Times

Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks – NBCSports.com

The Angels announced that starter Griffin Canning is getting a biological injection in his ailing elbow and will be re-evaluated in 3-4 weeks time. Canning was recently diagnosed with both UCL and joint issues in his pitching elbow.

The phrasing of the announcement is interesting. The word biological generally leads me in two different directions with this sort of injury. Many baseball players have been treated with platelet-rich plasma (PRP) injections for a variety of issues in recent years, but the Angels have also used stem cell injections to try to treat UCL woes.

Andrew Heaney, Garrett Richards and Shohei Ohtani all got stem cell treatments for their elbows. All three also eventually wound up getting Tommy John surgery. Im not willing to go as far as the LA Times article did in condemning the treatments as useless, seeing as a sample size of three is rather small. Theyre also not the only players who have ever been treated with stem cells. CC Sabathia, for instance, got a stem cell injection for his bad knee.

Regardless of what the treatment is or isnt, its a positive sign that Cannings injury wasnt deemed dire enough to immediately merit surgery. Canning isnt going to be ready for Opening Day either way, but if the injection works he may be able to pitch at some point this season. Goodness knows that the Angels rotation needs all hands on deck, even after the team signed both Dylan Bundy and Julio Teheran this winter.

Follow @StelliniTweets

The Indians announced via Twitter that Shane Bieber will be the teams Opening Day starter.

Its been a meteoric rise for Bieber. After a relatively pedestrian rookie year in 2018, Bieber rocketed to stardom in his sophomore campaign. The right-hander pitched to a 3.28 ERA in 214.1 innings, making the All-Star team and getting fourth place in the Cy Young Award voting along the way. Hes just 24 years old and figures to be a fixture atop the Cleveland rotation for years to come.

With Mike Clevinger still sidelined after undergoing arthroscopic surgery on his knee and Corey Kluber being traded to the Rangers, Bieber was the clear favorite for the nod.

Follow @StelliniTweets.

See the original post:
Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks - NBCSports.com

Beating heart cells catch a ride to the International Space Station – KTVZ

Tiny heart cells are among the new batch of science experiments heading for the International Space Station Friday night, but their potential to help patients with heart disease on Earth is exponential.

SpaceXs 20th resupply mission to the station is expected to launch Friday night at 11:50 p.m. ET from Cape Canaveral Air Force Station in Florida. It includes supplies, a variety experiments and materials for ongoing research investigations. The Dragon spacecraft will also bring the European Space Agencys Bartolomeo, a commercial research platform that will be installed outside the station, according to NASA.

And nestled among the payloads are two different experiments involving cariomyocytes, or beating heart cells, grown from pluripotent stem cells. Pluripotent stem cells are ideal because they can turned in multiple cell types. In this case, they could become healthy heart cells for a patient with heart disease.

The results of the experiments could be used to generate a multitude of healthy heart cells for children and adults with various heart diseases. But they could also be used to understand heart health and the aging process in a broader context. The researchers for one of the experiments believe their study could even help astronauts with the known risks they experience during long-term spaceflight, like reduced heart function and irregular heartbeat.

Scientists already know that humans exposed to space experience changes similar to accelerated aging, so we hope the results can help us better understand and someday counteract the aging process, said Deok-Ho Kim, principal investigator for one of the experiments, and associate professor of biomedical engineering and medicine at Johns Hopkins University.

For the next month, the heart cells will undergo a unique journey to space before splashing back down in the Pacific Ocean. Heres what researchers hope to learn about the effects of zero gravity on human heart cells.

Emory University School of Medicine associate professor of pediatrics Chunhui Xu first discovered that stem cells grow faster in space by simulating the lack of gravity on Earth. She studies cardiomyocytes with the hopes of improving the hearts regenerative abilities, as well as improving congenital heart disorder treatment.

Stem cell therapies to repair damaged heart cells require at least one billion cells for each patient, Xu said. But they can take time to grow on Earth. When her experiment using simulated microgravity on Earth showed promising steps toward quickly and safely producing cardiomyocytes, Xu saw space as the ultimate proving ground.

Her experiment was chosen to fly on the space station and now she and her team hope they can confirm their ground-based observation and discover new insights as well.

She and her colleagues at Emory had to learn how to cryopreserve the cells so that they can survive the launch and trip to the space station. It also means that the astronauts can unpack everything and organize their experiment schedule, without having to jump right into the experiment for fear of the cells dying.

Once the cells are thawed, the cell cultures will grow for 21 days in the Multi-use Variable-gravity Platform experiment modules built by Techshot, Inc. Then, in an ambitious goal, the cells will actually be returned live, jettisoned in a payload that will land in the Pacific Ocean. A colleague in California will then prep them and have the live cells shipped back to Emory in Atlanta so the researchers can analyze them.

Meanwhile, during the experiment in space, a control group of cells will be put in a centrifuge in a modified gravity environment on Earth.

Weve worked together for years to bring basic and clinical science together, said Dr. Kevin Maher, director of the cardiac intensive care unit at Childrens Healthcare of Atlanta Heart Center and professor of pediatrics at Emory University. Maher is working with Xu on the experiment.

Theres a high demand on the cells themselves they need to be pure and high quality. Residual stem cells that dont turn into heart cells can cause tumors, according to previous research by Xu. More mature cells stand a better chance of becoming pure heart cells. During her ground-based experiment simulating a lack of gravity, Xu found that the cells were more mature and even expressed survival genes that could ensure cell survival. Overall, these factors would allow the cells to connect with the heart tissue better and cause less issues, Xu said.

The implications of their research could help develop a more efficient and cost-effective way to develop the heart cells on Earth for patients in need. Given that heart disease is the leading cause of death in the US, according to the CDC, the cells have great potential to treat children and adults. And the cells could also be used to test new therapies and speed up the development of safe drugs, Xu said.

The National Center for Advancing Translational Sciences is continuing its Tissue Chips in Space initiative by funding an experiment that includes a cellphone-sized chip loaded with beating heart tissue.

It starts with a similar base as the Emory experiment: pluripotent stem cells grown into cardiomyocytes. Instead of cell cultures, these are bioengineered mini tissue chips that mimic human heart function.

This allows the cells to signal and act as they would in the body, hosted on a scaffold-like bio-structure holding the tissues together. This encourages the cells inside to grow, and ultimately, this kind of structure could be used to test drugs.

We hope that this project will give us meaningful data that we can use to understand the hearts structure and how it functions, so that we can improve the health of both astronauts and those down here on Earth, said Kim.

The Johns Hopkins University researchers and their collaborating colleagues at other universities will get measurements of the tissues beating in real time. And after a month, the tissues will return to Earth. The team wants to analyze them and determine how they were affected by microgravity or if their gene expression changed. Heart tissues on Earth, identical to the ones sent to the station, will serve as a control at the University of Washington.

Some of the tissues sent to space will continue to be cultured on Earth for a week afterward in case any recovery efforts can be observed.

The entire team is excited to see the results we get from this experiment. If successful, we will embark on the second phase of the study where tissues will be sent up to the ISS once again in two years, but this time, we will be able to test a variety of drugs to see which ones will best ameliorate the potentially harmful effects of microgravity on cardiac function, said Jonathan Tsui, a member of Kims lab and a postdoctoral fellow at Johns Hopkins Universitys department of biomedical engineering.

Continued here:
Beating heart cells catch a ride to the International Space Station - KTVZ

SpaceX Dragon to launch heart cell experiment and more to space station tonight – Space.com

CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.

This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.

The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.

You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).

Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.

In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.

To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.

By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.

Related: Adidas launching new sneakers inspired by historic NASA spacesuits

Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.

Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.

To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.

Related: Showering in space: Astronaut home video shows off 'hygiene corner'

"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."

He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.

"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."

Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.

Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.

The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.

The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.

Related: Heart cells beat differently in microgravity, may benefit astronauts

Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.

"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."

In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.

Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.

Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.

"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.

And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.

The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)

If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.

Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.

View post:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com